Navigation Links
OHSU is part of national effort to preserve, restore fertility in women with cancer
Date:9/11/2007

Portland, Ore. - The Oregon National Primate Research Center and the Oregon Health & Science University School of Medicine have been named to a national team of institutions hoping to preserve or restore fertility in women battling cancer. The Oncofertility Consortium, funded for five years by the National Institutes of Health, features participants from five universities and comprises researchers, physicians, engineers, educators, social workers and medical ethicists.

Biomedical research has helped save the lives of many women battling cancer, explained Richard Stouffer, Ph.D., director of the research team at OHSU. Stouffer also directs ONPRCs reproductive sciences division and is a professor of obstetrics and gynecology in the OHSU School of Medicine. However, the powerful chemotherapy drugs and radiation used to beat cancer can also result in a loss of reproductive function, which is a tremendous blow to young cancer patients who hope to have children. The bottom-line goal for this research team across the United States is to help these women through various avenues including research, treatment and counseling.

Additional members of the OHSU research team include Mary Zelinski, Ph.D., an affiliate assistant scientist at ONPRC, and David Lee, M.D., an assistant professor of obstetrics and gynecology, reproductive endocrinology and infertility in the OHSU School of Medicine.

Together the scientists are working on methods for restoring fertility in cancer patients by studying rhesus macaque monkeys who have reproductive systems very similar to humans. Specifically, the team is hoping to gain additional understanding about the growth of follicles in the ovaries and either to preserve or restart this function. Follicle growth is necessary for the development of oocytes (fertile eggs) in the ovaries.

Past research has demonstrated that cancer therapies often destroy follicles in the ovaries, thereby reducing fertilit
'/>"/>

Contact: Jim Newman
newmanj@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. International community warns India on HIV situation
2. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
3. National Lung Study in the process
4. Indian Nationals with Foreign Medical Degrees can now practice in India
5. Key step forward on International Health Rules
6. ICMR along with other International Research organisation with drug development for Neglected Diseases
7. International Osteoporosis Research Centre To Be Started In India.
8. Hepatitis B Vaccine To Be Included In National Immunization Programme
9. Indian hospitals require International Accreditation
10. International Conference On Malaria - Laveran To Genomics
11. UK Govt Says On Course For National Chlamydia Screening
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Autism Speaks Applauds Supreme Court Decision Upholding Families' Right to Challenge IEPs Without First Trying Out School District Proposed Placement 2Health News:Autism Speaks Applauds Supreme Court Decision Upholding Families' Right to Challenge IEPs Without First Trying Out School District Proposed Placement 3Health News:Mouse mammary tumor virus can replicate in human cells 2Health News:Health IT Now! Coalition Applauds Representatives Eshoo and Rogers for Introducing Health IT Legislation 2Health News:Salmonella Outbreak Traced to Banquet and Store Brand Frozen Pot Pies 2Health News:PRI Criticizes Guttmacher Report 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 3Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 4Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 5
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 1Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 2Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 3Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 1Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 2DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 1DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 2
Other Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures 2